Weathering the storm when the end of the road is near: A qualitative analysis of supportive care needs during CAR T-cell therapy in pediatrics.
adolescent and young adult
cancer
palliative care
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
12 Jun 2024
12 Jun 2024
Historique:
revised:
26
04
2024
received:
01
03
2024
accepted:
10
05
2024
medline:
13
6
2024
pubmed:
13
6
2024
entrez:
13
6
2024
Statut:
aheadofprint
Résumé
Chimeric antigen receptor (CAR) T-cell therapy provides promising outcomes in relapsed/refractory B acute lymphoblastic leukemia (ALL), yet still carries high toxicity rates and relatively poor long-term survival. Efficacy has yet to be demonstrated in other diagnoses while toxicity and risk profiles remain formidable. To date, treatment-related symptom burden is gleaned from clinical trial toxicity reports; the patient perspective remains understudied. English- or Spanish-speaking patients (ages 8-25 years) undergoing CAR T-cell therapy for any malignancy and their primary caregivers were recruited from Seattle Children's Hospital (SCH), St. Jude Children's Research Hospital (SJCRH), and the Pediatric Oncology Branch of the National Cancer Institute (NCI). Both patient and caregiver completed semi-structured dyadic interviews 3 months post treatment. We used directed content analysis for codebook development and thematic network analysis for inductive qualitative analysis. Twenty families completed interviews (13 patients, 15 parents). Patients were a median age 16.5 years, predominantly female (65%), White (75%), and diagnosed with ALL (75%). Global themes included "A clear decision," "Coping with symptoms," and "Unforeseen psychosocial challenges." When families were asked to describe the "most challenging part of treatment," most described "the unknown." Most reported "the symptoms really weren't that bad," even among patients hospitalized for severe toxicity events. Fatigue, pain, and nausea were the most prevalent symptoms. Importantly, only one family would have chosen a different therapy, if given another opportunity. Although physical symptoms were largely tolerable, recognizing supportive care opportunities remains imperative, particularly psychosocial concerns.
Sections du résumé
BACKGROUND
BACKGROUND
Chimeric antigen receptor (CAR) T-cell therapy provides promising outcomes in relapsed/refractory B acute lymphoblastic leukemia (ALL), yet still carries high toxicity rates and relatively poor long-term survival. Efficacy has yet to be demonstrated in other diagnoses while toxicity and risk profiles remain formidable. To date, treatment-related symptom burden is gleaned from clinical trial toxicity reports; the patient perspective remains understudied.
METHODS
METHODS
English- or Spanish-speaking patients (ages 8-25 years) undergoing CAR T-cell therapy for any malignancy and their primary caregivers were recruited from Seattle Children's Hospital (SCH), St. Jude Children's Research Hospital (SJCRH), and the Pediatric Oncology Branch of the National Cancer Institute (NCI). Both patient and caregiver completed semi-structured dyadic interviews 3 months post treatment. We used directed content analysis for codebook development and thematic network analysis for inductive qualitative analysis.
RESULTS
RESULTS
Twenty families completed interviews (13 patients, 15 parents). Patients were a median age 16.5 years, predominantly female (65%), White (75%), and diagnosed with ALL (75%). Global themes included "A clear decision," "Coping with symptoms," and "Unforeseen psychosocial challenges." When families were asked to describe the "most challenging part of treatment," most described "the unknown." Most reported "the symptoms really weren't that bad," even among patients hospitalized for severe toxicity events. Fatigue, pain, and nausea were the most prevalent symptoms. Importantly, only one family would have chosen a different therapy, if given another opportunity.
CONCLUSIONS
CONCLUSIONS
Although physical symptoms were largely tolerable, recognizing supportive care opportunities remains imperative, particularly psychosocial concerns.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e31092Subventions
Organisme : T32 Training
ID : 5T32CA009351-40
Organisme : Intramural Program of the National Cancer Institute
Organisme : NIH HHS
Pays : United States
Organisme : American Lebanese Syrian Associated Charities
Organisme : NHLBI NIH HHS
Pays : United States
Organisme : Conquer Cancer Foundation
Organisme : St. Baldrick's Foundation
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Butler E, Ludwig K, Pacenta HL, Klesse LJ, Watt TC, Laetsch TW. Recent progress in the treatment of cancer in children. CA Cancer J Clin. 2021;71(4):315‐332. doi:10.3322/caac.21665
Scott EC, Baines AC, Gong Y, et al. Trends in the approval of cancer therapies by the FDA in the twenty‐first century. Nat Rev Drug Discov. 2023;22(8):625‐640. doi:10.1038/s41573‐023‐00723‐4
Hunger SP, Raetz EA. How I treat relapsed acute lymphoblastic leukemia in the pediatric population. Blood. 2020;136(16):1803‐1812. doi:10.1182/blood.2019004043
Lin YJ, Mashouf LA, Lim M. CAR T cell therapy in primary brain tumors: current investigations and the future. Front Immunol. 2022;13:817296. doi:10.3389/fimmu.2022.817296
Del Bufalo F, De Angelis B, Caruana I, et al. GD2‐CART01 for relapsed or refractory high‐risk neuroblastoma. N Engl J Med. 2023;388(14):1284‐1295. doi:10.1056/NEJMoa2210859
Shah NN, Lee DW, Yates B, et al. Long‐term follow‐up of CD19‐CAR T‐cell therapy in children and young adults with B‐ALL. J Clin Oncol. 2021;39(15):1650‐1659. doi:10.1200/JCO.20.02262
Long KB, Young RM, Boesteanu AC, et al. CAR T cell therapy of non‐hematopoietic malignancies: detours on the road to clinical success. Front Immunol. 2018;9:2740. doi:10.3389/fimmu.2018.02740
Webb JA, Kamal AH, LeBlanc TW. A new frontier for palliative care: the need to train palliative‐oncology subspecialists. J Palliat Med. 2018;21(12):1679‐1680. doi:10.1089/jpm.2018.0421
Freedman JL, Beeler DM, Bowers A, et al. Supportive care in pediatric oncology: opportunities and future directions. Cancers (Basel). 2023;15(23):5549. doi:10.3390/cancers15235549
Sampetrean A, Aldea M, Mateus C. Precision medicine's new frontier: integrating palliative care at the right time. ESMO Open. 2023;8(5):101632. doi:10.1016/j.esmoop.2023.101632
Weaver MS, Heinze KE, Kelly KP, et al. Palliative care as a standard of care in pediatric oncology. Pediatr Blood Cancer. 2015;62:S829‐S833. doi:10.1002/pbc.25695
Wiener L, Kazak AE, Noll RB, Patenaude AF, Kupst MJ. Standards for the psychosocial care of children with cancer and their families: an introduction to the special issue. Pediatr Blood Cancer. 2015;62(Suppl 5):S419‐S424. doi:10.1002/pbc.25675
Temel JS, Shaw AT, Greer JA. Challenge of prognostic uncertainty in the modern era of cancer therapeutics. J Clin Oncol. 2016;34(30):3605‐3608. doi:10.1200/JCO.2016.67.8573
Maude SL. Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2018;16(10):664‐666.
Ruark J, Mullane E, Cleary N, et al. Patient‐reported neuropsychiatric outcomes of long‐term survivors after chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant. 2020;26(1):P34‐P43. doi:10.1016/j.bbmt.2019.09.037
Akinola IM, Cusatis R, Pasquini MC, et al. Multi‐stakeholder qualitative interviews to inform measurement of patient reported outcomes after CAR‐T. Transplant Cell Ther. 2023;29(4):254.e1‐e9. doi:10.1016/j.jtct.2023.01.004
Whisenant MS, Srour SA, Williams LA, et al. The unique symptom burden of patients receiving CAR T‐cell therapy. Semin Oncol Nurs. 2021;37(6):151216. doi:10.1016/j.soncn.2021.151216
Steineck A, Wiener L, Mack JW, Shah NN, Summers C, Rosenberg AR. Psychosocial care for children receiving chimeric antigen receptor (CAR) T‐cell therapy. Pediatr Blood Cancer. 2020;67(5):e28249. doi:10.1002/pbc.28249
Chakraborty R, Sidana S, Shah GL, Scordo M, Hamilton BK, Majhail NS. Patient‐reported outcomes with chimeric antigen receptor T cell therapy: challenges and opportunities. Biol Blood Marrow Transplant. 2019;25(5):e155‐e162. doi:10.1016/j.bbmt.2018.11.025
Efficace F, Cannella L, Sparano F, et al. Chimeric antigen receptor T‐cell therapy in hematologic malignancies and patient‐reported outcomes: a scoping review. Hemasphere. 2022;6(12):e802. doi:10.1097/HS9.0000000000000802
Stenson CL, Vidrine J, Dewhurst F, Osborne W, Menne T, Stocker R. A qualitative service evaluation of patient and caregiver experiences of CAR‐T therapy: recommendations for service development and implications for palliative care teams. Palliat Med. 2023;37(2):215‐220. doi:10.1177/02692163221138880
O'Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med. 2014;89(9):1245‐1251. doi:10.1097/ACM.0000000000000388
Wilson IB, Cleary PD. Linking clinical variables with health‐related quality of life. A conceptual model of patient outcomes. JAMA. 1995;273(1):59‐65.
Collins JJ, Byrnes ME, Dunkel IJ, et al. The measurement of symptoms in children with cancer. J Pain Symptom Manage. 2000;19(5):363‐377.
Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277‐1288. doi:10.1177/1049732305276687
Vaismoradi M, Turunen H, Bondas T. Content analysis and thematic analysis: implications for conducting a qualitative descriptive study. Nurs Health Sci. 2013;15(3):398‐405. doi:10.1111/nhs.12048
Attride‐Stirling J. Thematic networks: an analytic tool for qualitative research. Qual Res. 2001;1(3):385‐405. doi:10.1177/146879410100100307
Elo S, Kyngas H. The qualitative content analysis process. J Adv Nurs. 2008;62(1):107‐115. doi:10.1111/j.1365‐2648.2007.04569.x
Burns NA, Grove SK. The Practice of Nursing Research: Conduct, Critique and Utilization. 5th ed. Elsevier Saunders; 2005.
Saunders B, Sim J, Kingstone T, et al. Saturation in qualitative research: exploring its conceptualization and operationalization. Qual Quant. 2018;52(4):1893‐1907. doi:10.1007/s11135‐017‐0574‐8
Robertson EG, Wakefield CE, Shaw J, et al. Decision‐making in childhood cancer: parents' and adolescents' views and perceptions. Support Care Cancer. 2019;27(11):4331‐4340. doi:10.1007/s00520‐019‐04728‐x
Sisk BA, Kang TI, Mack JW. The evolution of regret: decision‐making for parents of children with cancer. Support Care Cancer. 2020;28(3):1215‐1222. doi:10.1007/s00520‐019‐04933‐8
Feifer D, Broden EG, Xiong N, et al. Mixed‐methods analysis of decisional regret in parents following a child's death from cancer. Pediatr Blood Cancer. 2023;70(10):e30541. doi:10.1002/pbc.30541
Wakefield CE, Hetherington K, Robertson EG, et al. Hopes, concerns, satisfaction and regret in a precision medicine trial for childhood cancer: a mixed‐methods study of parent and patient perspectives. Br J Cancer. 2023;129(10):1634‐1644. doi:10.1038/s41416‐023‐02429‐1
Stewart JL, Mishel MH, Lynn MR, Terhorst L. Test of a conceptual model of uncertainty in children and adolescents with cancer. Res Nurs Health. 2010;33(3):179‐191. doi:10.1002/nur.20374
Blazin LJ, Cecchini C, Habashy C, Kaye EC, Baker JN. Communicating effectively in pediatric cancer care: translating evidence into practice. Children (Basel). 2018;5(3):40. doi:10.3390/children5030040
Mack JW, Kang TI. Care experiences that foster trust between parents and physicians of children with cancer. Pediatr Blood Cancer. 2020;67(11):e28399. doi:10.1002/pbc.28399
Herts KL, Khaled MM, Stanton AL. Correlates of self‐efficacy for disease management in adolescent/young adult cancer survivors: a systematic review. Health Psychol. 2017;36(3):192‐205. doi:10.1037/hea0000446
Brammer JE, Braunstein Z, Katapadi A, et al. Early toxicity and clinical outcomes after chimeric antigen receptor T‐cell (CAR‐T) therapy for lymphoma. J Immunother Cancer. 2021;9(8). doi:10.1136/jitc-2020-002303
Newman H, Li Y, Liu H, et al. Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19‐directed CAR T‐cell therapy. Blood. 2023;141(6):609‐619. doi:10.1182/blood.2022017866
Hall AG, Winestone LE, Sullivan EM, et al. Access to chimeric antigen receptor T cell clinical trials in underrepresented populations: a multicenter cohort study of pediatric and young adult acute lymphobastic leukemia patients. Transplant Cell Ther. 2023;29(6):356 e1‐356 e7. doi:10.1016/j.jtct.2023.03.022